Company: PRTA
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001559053-25-000023
Chunk: 7

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 7
---
 liabilities consisted of the following (in thousands):

                                    March 31,                 December 31,              
                                    2025                      2024                      
 ────────────────────────────────────────────────────────────────────────────────────────
  Payroll and related expenses      $              7,284      $                 14,468  
  Professional services             356                       445                       
  Other                                            1,586      930                       
  Other current liabilities         $              9,226      $                 15,843  

5. Net Loss Per Ordinary Share

Net loss per ordinary share was determined as follows (in thousands, except per share amounts):

                                                                                   Three Months Ended                                          
                                                                                   March 31,                                                   
                                                                                   2025                                   2024                 
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Numerator:                                                                                                                                   
  Net loss                                                                         $                       ( 60,195)      $         ( 72,239)  
  Denominator:                                                                                                                                 
  Weighted-average ordinary shares outstanding used in per share calculations                                 53,827                   53,714  
  Net loss per share:                                                                                                                          
  Basic and diluted net loss per ordinary share                                    $                         ( 1.12)      $           ( 1.34)  

Potentially issuable ordinary shares were not used in computing diluted net loss per ordinary share as their effect would be anti-dilutive due to the loss recorded during the three months ended March 31, 2025 and 2024, and therefore diluted net loss per share is equal to basic net loss per share.

The equivalent ordinary shares not included in diluted net income (loss) per share because their effect would be anti-dilutive are as follows (in thousands):

                                                 Three Months Ended                                    
                                                          March 31,                                    
                                                               2025                  2024              
 ───────────────────────────────────────────────────────────────────────────────────────────────────────
  Stock options to purchase ordinary shares                              12,835                11,751  
  Restricted Stock Units (RSU)                                  291                    25              
  Total                                                                  13,126                11,776  

6. Commitments and Contingencies

Lease Commitments

As ofMarch 31, 2025, the Company currently has four leases relating to its facilities in the United States and Dublin, Ireland.

Dublin

In June 2021, the Company entered into a lease agreement for